<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vulvar and vaginal intraepithelial neoplasia in patients with HIV infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vulvar and vaginal intraepithelial neoplasia in patients with HIV infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vulvar and vaginal intraepithelial neoplasia in patients with HIV infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William R Robinson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 20, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with HIV infection are at an increased risk of vulvar and vaginal neoplasia [<a href="#rid1">1-5</a>]. As with cervical neoplasia, the incidence and severity of vulvar and vaginal premalignant and malignant disease appear to correlate with worsening immunosuppression [<a href="#rid6">6-8</a>]. Furthermore, despite standard therapy, patients with HIV with vulvar or vaginal neoplasia have higher rates of persistence and recurrence than the general population, again similar to cervical neoplasia [<a href="#rid9">9,10</a>].</p><p>Screening, diagnosis, and treatment for vulvar and vaginal intraepithelial neoplasia (VIN and VaIN) in patients with HIV infection will be reviewed here. Vulvar and vaginal neoplasia in the general population are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)"</a> and  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>The Vulvar Oncology Subcommittee of the International Society for the Study of Vulvar Disease (ISSVD) published a classification system for VIN in 2004 [<a href="#rid11">11</a>]. The term VIN was limited to histologically high-grade squamous lesions (formerly termed VIN 2 and VIN 3), for which treatment is indicated to prevent progression to cancer [<a href="#rid11">11</a>]. Lesions previously referred to as VIN 1 were no longer classified as VIN. This topic review will adhere to the 2004 ISSVD nomenclature except when data are reported from studies that used the previous classification. (See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Terminology and epidemiology'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>VIN and VaIN are precursors to vulvar and vaginal cancer and are more common in patients infected with HIV [<a href="#rid12">12-14</a>]. In the general United States population, the estimated incidence of VIN and VaIN is 2.9 and 0.2 to 0.3 per 100,000 females, respectively. (See  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Epidemiology'</a>.)</p><p>The incidence of VIN and VaIN in patients with HIV infection has not been extensively studied, but the available data are consistent with increased risk:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study, 5 of 385 patients with HIV followed for a median of 3.2 years developed new high-grade vulvar/perianal intraepithelial neoplasia compared with 0 of 341 patients without HIV infection [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another prospective study, the incidence of VaIN at six-year follow-up was 3 of 192 patients with HIV compared with 0 of 88 patients without HIV infection [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective study (n = 410) of patients who had undergone hysterectomy found a statistically significantly increased rate of VaIN 2 or vaginal cancer in patients with compared to without HIV infection (0.2 versus 0.01 per 100 person-years) [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Human papillomavirus (HPV) infection is the primary etiology of vulvar, vaginal, and cervical neoplasia [<a href="#rid16">16</a>]. HPV and HIV interact in several ways that are relevant to VIN and VaIN:</p><p class="bulletIndent1"><span class="glyph">●</span>HPV and HIV infection share a sexual route of transmission, and therefore, the vulnerable populations often coincide.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV-mediated immunosuppression results in exacerbation of HPV infection, and an increased incidence and severity of high-grade vulvar and vaginal lesions [<a href="#rid17">17,18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection appears to impair local mechanisms of lower genital tract immunity, as demonstrated by a decreased Langerhans cell density in vulvar tissue in patients with HIV infection [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H6220137"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Human papillomavirus (HPV) vaccination decreases the incidence of vulvar and vaginal neoplasia. This was demonstrated in a randomized trial of 5455 healthy females ages 16 to 24 years with no history of genital warts or abnormal cervical cytology who were assigned to receive the quadrivalent HPV vaccine (HPV types 6, 11, 16, 18) or a placebo injection [<a href="#rid20">20</a>]. At an average of three-year follow-up, there were fewer cases of grade 2 or 3 VIN or VaIN in patients in the vaccine group than in the placebo group (0.1 versus 0.2 percent); however, the trial did not have sufficient statistical power to assess whether the difference was significant (efficacy 62 percent, 95% CI &lt;0-89). At the start of the study, 13 to 14 percent of patients tested positive for infection with one or more of the HPV types included in the vaccine. Excluding these patients from the analysis did not alter the magnitude of the effect of vaccination; the rates of grade 2 or 3 VIN or VaIN for the vaccine and placebo groups were 0.04 versus 0.1 percent. Additional details of this trial are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination", section on 'Efficacy'</a>.)</p><p>The safety or efficacy of the available HPV types 16 and 18 vaccine in preventing vulvar or vaginal neoplasia in patients with HIV infection is unknown. It appears that it can be used in immunosuppressed patients, since it is not a live vaccine. (See  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination", section on 'Patients with HIV or immunocompromising conditions'</a>.)</p><p>However, the vaccine may be less effective since the distribution of HPV subtypes in patients with HIV infection is typically different from that seen in HIV-negative patients. (See  <a class="medical medical_review" href="/z/d/html/3245.html" rel="external">"Preinvasive and invasive cervical neoplasia in patients with HIV infection", section on 'Role of HPV vaccination'</a> and  <a class="medical medical_review" href="/z/d/html/8314.html" rel="external">"Human papillomavirus infections: Epidemiology and disease associations", section on 'Females'</a>.)</p><p>Given that HPV vaccination may offer some benefit to patients with HIV infection and is not contraindicated in patients with immunosuppression, we suggest HPV vaccination in patients with HIV. Either the quadrivalent (HPV types 6, 11, 16, 18) or bivalent (HPV types 16 and 18) formulation can be used, but the quadrivalent vaccine offers the additional potential benefit of prevention of anogenital warts associated with HPV types 6 and 11, which can be extensive in immunosuppressed patients. (See  <a class="medical medical_review" href="/z/d/html/99981.html" rel="external">"Condylomata acuminata (anogenital warts) in adults: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p>Preexisting lower genital neoplasia is not a contraindication to HPV vaccination, since an individual may be infected with one but not all of the HPV subtypes included in the vaccine. Current HPV vaccines are for subtypes 16 and 18 or 16, 18, 6, and 11. The predominant HPV subtypes for vulvar cancer appear to be 16 and 33 and for vaginal cancer, 16 and 18 [<a href="#rid21">21</a>]. However, other oncogenic subtypes may be present. There are few adverse effects of vaccination. The decision of whether to vaccinate a patient with established vulvar or vaginal intraepithelial neoplasia must be based on whether the cost justifies the limited benefit.</p><p>Type-specific testing for HPV 16 and 18 is not useful for identifying patients who should not receive the vaccine, since HPV infection can be transient and it is not known if previous HPV infection is protective against reinfection. (See  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination", section on 'Pre-existing HPV-associated disease'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Clinical manifestations of VIN and VaIN in patients with HIV infection are the same as for patients without HIV infection. Approximately 50 percent of patients with VIN are asymptomatic. In symptomatic patients, the most common complaint is vulvar pruritus; other presentations include perineal pain or burning, dysuria, a visible lesion, or a palpable abnormality. (See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Clinical presentation'</a>.)</p><p>VaIN is nearly always asymptomatic, but some patients present with postcoital spotting or vaginal discharge. (See  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">SURVEILLANCE</span><span class="headingEndMark"> — </span>VIN and VaIN are rare conditions, and screening is not routinely performed in the general population. Although patients with HIV infection have an increased risk of these conditions, there are no data or guidelines regarding screening patients with HIV for vulvar or vaginal cancer.</p><p>By contrast, multiple expert groups have devised consensus guidelines for cervical cancer screening in patients with HIV; this is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3220.html" rel="external">"Screening for cervical cancer in patients with HIV infection and other immunocompromised states", section on 'Our approach to screening'</a>.)</p><p>Patients with HIV should, therefore, undergo a pelvic examination annually, at minimum. We suggest that patients with HIV undergo a careful vulvar and vaginal examination whenever a pelvic examination is performed for cervical cancer screening or for another indication (with the exception of focused examinations during which vulvar or vaginal examination for neoplasia would not be practical).</p><p>In our practice, we examine patients who are immunosuppressed (CD4 cell count &lt;200/mm<sup>3</sup>) or have a viral load of ≥500 copies/mL at least every six months.</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>VIN and VaIN are histologic diagnoses based upon vulvar or vaginal biopsy. Biopsy may be directed by gross visual examination of lesions or by examination under magnification with a colposcope or hand-held magnifying device.</p><p>Indications for a diagnostic evaluation are:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical manifestations of VIN or VaIN</p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal or vulvar lesions that are suspicious for neoplasia</p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal cervical cytology, if a cervical lesion is not identified</p><p></p><p>Aspects of evaluation for VIN and VaIN that are specific to patients with HIV infection are described here. General techniques for vulvar and vaginal examination and biopsy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5450.html" rel="external">"Vulvar lesions: Diagnostic evaluation", section on 'Basic examination'</a> and  <a class="medical medical_review" href="/z/d/html/5450.html" rel="external">"Vulvar lesions: Diagnostic evaluation", section on 'Additional procedures'</a> and  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia", section on 'Diagnostic evaluation'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Vulvar neoplasia</span></p><p class="headingAnchor" id="H10"><span class="h3">Vulvar examination</span><span class="headingEndMark"> — </span>A complete examination is performed of areas with potential squamous neoplasia. In patients with HIV, this includes examination of the vulva as well as the perineum and perianal areas.</p><p>VIN is highly variable in appearance and may be a subtle visual finding. In the general population, VIN is commonly located between the 3:00 and 9:00 positions along the labia minora and the introitus (mapping vulvar sites according to locations around a clock face). In patients with HIV, VIN may be more extensive and scattered. Lesions may involve the clitoris, urethra, anus, and intergluteal cleft and can easily be overlooked [<a href="#rid22">22</a>].</p><p>Characteristics of vulvar lesions and techniques for vulvar examination and evaluation of anal lesions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5450.html" rel="external">"Vulvar lesions: Diagnostic evaluation", section on 'Basic examination'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Vulvar colposcopy and biopsy</span><span class="headingEndMark"> — </span>Colposcopy or examination using a hand-held magnifying glass may be useful for some vulvar lesions. We use magnification to examine any small lesion that is visible but is difficult to see with the unaided eye. Biopsy is performed of all lesions that are not obviously benign (eg, epidermoid cysts, often erroneously referred to as sebaceous cysts). (See  <a class="medical medical_review" href="/z/d/html/5412.html" rel="external">"Vulvar lesions: Differential diagnosis of vesicles, bullae, erosions, and ulcers"</a>.)</p><p>The techniques for vulvar colposcopy and biopsy are reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3260.html" rel="external">"Colposcopy", section on 'Vulvar colposcopy'</a> and  <a class="medical medical_review" href="/z/d/html/5450.html" rel="external">"Vulvar lesions: Diagnostic evaluation", section on 'Use of biopsy'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Vaginal neoplasia</span></p><p class="headingAnchor" id="H13"><span class="h3">Vaginal examination</span><span class="headingEndMark"> — </span>During the vaginal examination, attempts are made to visualize lesions while using a speculum and to palpate lesions with a manual examination. VaIN may be difficult to visualize without magnification, and is therefore usually detected with cytology. When it is visible, it is generally white in appearance, with sharp borders and a granular texture. VaIN may be multifocal, particularly in patients with HIV.</p><p class="headingAnchor" id="H14"><span class="h3">Vaginal cytology, colposcopy, and biopsy</span><span class="headingEndMark"> — </span>Vaginal and cervical cytology is performed if these samples have not yet been obtained. Colposcopy is usually needed to visualize vaginal lesions. Biopsy is performed of all lesions that are suspicious for neoplasia. (See  <a class="medical medical_review" href="/z/d/html/3260.html" rel="external">"Colposcopy", section on 'Vaginal colposcopy'</a> and  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia", section on 'Biopsy technique'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Management of patients with HIV infection with VIN or VaIN involves treatment of lesions as well as of the underlying HIV infection.</p><p>Aspects of treatment for VIN and VaIN that are specific to patients with HIV infection are described here. General principles of VIN and VaIN treatment are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Vulvar neoplasia</span><span class="headingEndMark"> — </span>Conservative surgical excision and destruction of the lesions are the mainstays of therapy for VIN in patients with HIV, as they are in the general population. Total or even simple vulvectomy may be debilitating, particularly in immunosuppressed individuals, and is rarely required. (See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Treatment'</a>.)</p><p>Medical therapy of VIN is reserved for patients in whom excision with negative margins would necessitate significant vulvar mutilation (eg, clitoral, periurethral, or perianal lesions). There are few data regarding medical therapy for VIN (eg, <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>, <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a>, interferon alfa, retinoids) in patients with HIV [<a href="#rid23">23,24</a>]. Patients who fail treatment with topical therapy should be treated with surgical excision.</p><p class="headingAnchor" id="H17"><span class="h2">Vaginal neoplasia</span><span class="headingEndMark"> — </span>There are no data regarding treatment of VaIN in patients with HIV. The usual approach to treatment is the same as for the general population. Unifocal VaIN is treated with conservative surgical excision and destruction of the lesions. Multifocal or recurrent VaIN is best treated with topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a>. (See  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Highly active antiretroviral therapy</span><span class="headingEndMark"> — </span>Highly active antiretroviral therapy (HAART) appears to decrease the incidence and recurrence of VIN [<a href="#rid10">10,14</a>]. The magnitude of this effect was illustrated in a multicenter prospective study of 1562 HIV-positive patients [<a href="#rid14">14</a>]. Current or former use of HAART compared with no HAART use was associated with a one-third decrease in the incidence of VIN, which was statistically significant in a multivariate analysis that controlled for CD4 count and HIV RNA level. Based upon these data, we suggest HAART rather than no antiretroviral therapy for patients with HIV who are candidates for antiretroviral therapy and who have VIN. There are few data regarding the effect of HAART on vulvar cancer in patients with HIV [<a href="#rid14">14</a>].</p><p>Theoretically, HAART use should also decrease the incidence of VaIN and vaginal cancer, but no studies have investigated this question. This is likely because a beneficial effect is seen for VIN and cervical intraepithelial neoplasia, which have the same HPV-mediated pathophysiology as VaIN. As a result, we suggest use of HAART for patients with HIV with VaIN. (See  <a class="medical medical_review" href="/z/d/html/3245.html" rel="external">"Preinvasive and invasive cervical neoplasia in patients with HIV infection", section on 'Antiretroviral therapy'</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Information on the outcome of VIN and VaIN in patients with HIV infection is limited. In the general population, the risk of recurrence after treatment of VIN and VaIN ranges from 20 to 70 percent, and the risk of progression to invasive cancer ranges from 1 to 5 percent. The risk of recurrence of VIN/VaIN appears to be higher in patients with HIV than in other patients, as it is for cervical intraepithelial neoplasia [<a href="#rid25">25,26</a>]. As an example, in a study of patients with anogenital lesions, the recurrence rate after laser treatment was higher for patients with HIV compared with patients without HIV infection (26 versus 17 percent) [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Disease recurrence'</a> and  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia", section on 'Natural history'</a>.)</p><p>Long-term data on lower genital tract neoplasia in patients with HIV are limited. While it has been reported that multiple concurrent human papillomavirus-associated neoplasias may not be uncommon in patients with HIV, even in those whose disease is well-controlled as measured by CD4 and viral loads [<a href="#rid27">27</a>], the same authors previously found that the overall outcomes were similar to those seen in patients not infected with HIV in the same population with 20-year follow-up [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H4230002100"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113636.html" rel="external">"Society guideline links: Vulvar cancer and vaginal cancer"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HIV infection are at an increased risk of vulvar and vaginal neoplasia. The incidence and severity of vulvar and vaginal neoplasia appears to be correlated with worsening immunosuppression. (See <a class="local">'Incidence'</a> above and <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with HIV, we suggest human papillomavirus (HPV) vaccination (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Either the quadrivalent (HPV types 6, 11, 16, 18) or bivalent (HPV types 16 and 18) formulation can be used, but the quadrivalent vaccine offers the additional potential benefit of prevention of anogenital warts. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with vulvar intraepithelial neoplasia (VIN) or vaginal intraepithelial neoplasia (VaIN) are asymptomatic. In symptomatic patients with VIN, the most common complaint is vulvar pruritus. Patients with VaIN occasionally present with postcoital spotting or vaginal discharge. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest that patients with HIV undergo a careful vulvar and vaginal examination whenever a complete pelvic examination is performed (eg, for cervical cancer screening). (See <a class="local">'Surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with HIV with abnormal cervical cytology in whom a cervical lesion is not identified, we suggest that vaginal cytology and colposcopy be performed. (See <a class="local">'Surveillance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VIN and VaIN are histologic diagnoses made using vulvar or vaginal biopsy. Biopsy may be directed by gross visual examination of lesions or by examination under magnification with a colposcope or hand-held magnifying device. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with HIV with VIN or VaIN are treated the same as patients in the general population. Conservative surgical excision and destruction of lesions are the mainstays of therapy. Topical therapy is reserved for patients with multifocal disease. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with HIV with VIN or VaIN, we suggest highly active antiretroviral therapy rather than no antiretroviral therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Highly active antiretroviral therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Maiman M, Fruchter RG, Serur E, et al. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 1990; 38:377.</a></li><li><a class="nounderline abstract_t">Clark RA, Brandon W, Dumestre J, Pindaro C. Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana. Clin Infect Dis 1993; 17:165.</a></li><li class="breakAll">Robinson WR, Morris CB. Cervical Neoplasia: Pathogenesis, Diagnosis, and Management. In: Hematologic and Oncologic Aspects of HIV Infection - Hematology/Oncology Clinics of North America, Krown SE, Von Roenn JH (Eds), WB Saunders, Philadelphia 1996. Vol 10, p.1163.</li><li><a class="nounderline abstract_t">Korn AP, Abercrombie PD, Foster A. Vulvar intraepithelial neoplasia in women infected with human immunodeficiency virus-1. Gynecol Oncol 1996; 61:384.</a></li><li><a class="nounderline abstract_t">Chiasson MA, Ellerbrock TV, Bush TJ, et al. Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus. Obstet Gynecol 1997; 89:690.</a></li><li><a class="nounderline abstract_t">Spitzer M. Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Obstet Gynecol Surv 1999; 54:131.</a></li><li><a class="nounderline abstract_t">Schäfer A, Friedmann W, Mielke M, et al. The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 1991; 164:593.</a></li><li><a class="nounderline abstract_t">Robinson WR, Barnes SE, Adams S, Perrin MS. Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears. Gynecol Oncol 1997; 65:430.</a></li><li><a class="nounderline abstract_t">Maiman M, Fruchter RG, Clark M, et al. Cervical cancer as an AIDS-defining illness. Obstet Gynecol 1997; 89:76.</a></li><li><a class="nounderline abstract_t">Dedes KJ, Beneder C, Samartzis N, et al. Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women. J Reprod Med 2008; 53:947.</a></li><li><a class="nounderline abstract_t">Sideri M, Jones RW, Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med 2005; 50:807.</a></li><li><a class="nounderline abstract_t">Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.</a></li><li><a class="nounderline abstract_t">Jamieson DJ, Paramsothy P, Cu-Uvin S, et al. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet Gynecol 2006; 107:1023.</a></li><li><a class="nounderline abstract_t">Massad LS, Silverberg MJ, Springer G, et al. Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus. Am J Obstet Gynecol 2004; 190:1241.</a></li><li><a class="nounderline abstract_t">Massad LS, Xie X, Greenblatt RM, et al. Effect of human immunodeficiency virus infection on the prevalence and incidence of vaginal intraepithelial neoplasia. Obstet Gynecol 2012; 119:582.</a></li><li><a class="nounderline abstract_t">Huh WK. Human papillomavirus infection: a concise review of natural history. Obstet Gynecol 2009; 114:139.</a></li><li><a class="nounderline abstract_t">Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120.</a></li><li><a class="nounderline abstract_t">Brown JE, Sunborg MJ, Kost E, et al. Vulvar cancer in human immunodeficiency virus-seropositive premenopausal women: a case series and review of the literature. J Low Genit Tract Dis 2005; 9:7.</a></li><li><a class="nounderline abstract_t">Taube JM, Nichols AD, Bornman LS, et al. Langerhans cell density and high-grade vulvar intraepithelial neoplasia in women with human immunodeficiency virus infection. J Cutan Pathol 2007; 34:565.</a></li><li><a class="nounderline abstract_t">Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928.</a></li><li><a class="nounderline abstract_t">Daling JR, Madeleine MM, Schwartz SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002; 84:263.</a></li><li><a class="nounderline abstract_t">Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007; 15:130.</a></li><li><a class="nounderline abstract_t">Del Priore G, Herron MM. Retinoids for vulvar dysplasia in the HIV-infected patient. Int J Gynaecol Obstet 1996; 55:77.</a></li><li><a class="nounderline abstract_t">Wendling J, Saiag P, Berville-Levy S, et al. Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases. Arch Dermatol 2004; 140:1220.</a></li><li><a class="nounderline abstract_t">Ahr A, Rody A, Kissler S, et al. [Risk factors for recurrence of vulvar intraepithelial neoplasia III (VIN III)]. Zentralbl Gynakol 2006; 128:347.</a></li><li><a class="nounderline abstract_t">Aynaud O, Buffet M, Roman P, et al. Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplasia after CO2 laser treatment. Eur J Dermatol 2008; 18:153.</a></li><li><a class="nounderline abstract_t">Davis K, Rogg K, Robinson WR. The Incidence and Management of Human Papilloma Virus-Associated Malignancies in Immunocompetent Human Immunodeficiency Virus-Infected Women. Gynecol Oncol 2019.</a></li><li><a class="nounderline abstract_t">Robinson WR. Long-Term Follow-Up of HIV-Infected Women with Cervical Dysplasia. AIDS Patient Care STDS 2015; 29:517.</a></li></ol></div><div id="topicVersionRevision">Topic 3228 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2227552" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Human immunodeficiency virus infection and cervical neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399861" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399861" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical manifestations of infection with the human immunodeficiency virus in women in Louisiana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8641620" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Vulvar intraepithelial neoplasia in women infected with human immunodeficiency virus-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9166302" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Increased prevalence of vulvovaginal condyloma and vulvar intraepithelial neoplasia in women infected with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950005" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992708" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9190970" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8990442" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cervical cancer as an AIDS-defining illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160654" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16419625" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809252" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648406" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15167825" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effect of antiretroviral therapy on the incidence of genital warts and vulvar neoplasia among women with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22353957" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of human immunodeficiency virus infection on the prevalence and incidence of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546771" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Human papillomavirus infection: a concise review of natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648510" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk of human papillomavirus-associated cancers among persons with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870515" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vulvar cancer in human immunodeficiency virus-seropositive premenopausal women: a case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576336" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Langerhans cell density and high-grade vulvar intraepithelial neoplasia in women with human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17494926" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812085" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A population-based study of squamous cell vaginal cancer: HPV and cofactors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720998" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Human papillomavirus infection in HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8910089" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Retinoids for vulvar dysplasia in the HIV-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492184" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17213974" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : [Risk factors for recurrence of vulvar intraepithelial neoplasia III (VIN III)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18424374" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplasia after CO2 laser treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Incidence and Management of Human Papilloma Virus-Associated Malignancies in Immunocompetent Human Immunodeficiency Virus-Infected Women</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26430720" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-Term Follow-Up of HIV-Infected Women with Cervical Dysplasia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
